Loading
Chemotherapy drugs originally from the yew tree that freeze the cell's internal scaffolding (microtubules) so it cannot divide. Used in breast, lung, ovarian, prostate, gastric and head and neck cancers; their main lasting side effect is nerve damage in the hands and feet.
Paclitaxel (Taxol, 1992) and docetaxel are given with platinum in ovarian and lung cancer, sequentially with anthracyclines in breast cancer, as the chemotherapy partner in KEYNOTE-522 and CLEOPATRA, and as first chemotherapy in prostate cancer (docetaxel, then cabazitaxel after progression). Nab-paclitaxel is an albumin-bound form that avoids solvent hypersensitivity and is standard with gemcitabine in pancreatic cancer. Peripheral neuropathy, alopecia, neutropenia and hypersensitivity reactions are the main toxicities; taxane-derived payloads are less common in ADCs than tubulin inhibitors such as MMAE, which act on the same target.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Showing the molecule this term concerns: Paclitaxel / nab-paclitaxel.
The last major guideline written before KEYNOTE-522 changed the standard; the 2022 rapid update reversed the immunotherapy line within a year.
Chemotherapy works in receptor-negative disease at least as well as in receptor-positive disease in proportional terms, and because triple-negative absolute risk is high the absolute gain is large; this is why anthracycline and taxane backbone survived into KEYNOTE-522 and why SCARLET now asks whether the anthracycline can go.
Shares Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline, Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Cytotoxic chemotherapy.
Shares Peripheral neuropathy (chemotherapy-induced), Docetaxel, Paclitaxel / nab-paclitaxel, Cytotoxic chemotherapy.
Shares Docetaxel, Paclitaxel / nab-paclitaxel, Cytotoxic chemotherapy.
Shares Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem.
Shares Docetaxel, Paclitaxel / nab-paclitaxel, Cytotoxic chemotherapy.
Shares Peripheral neuropathy (chemotherapy-induced), Docetaxel, Paclitaxel / nab-paclitaxel.
Shares Docetaxel, Paclitaxel / nab-paclitaxel, Cytotoxic chemotherapy.
Shares Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem.